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Introduction. Polycystic ovary syndrome is a heterogeneous disorder characterized by 
hyperandrogenism, insulin resistance, metabolic disorders, anovulatory cycles and infertility, 
affecting 6% - 20% of women of reproductive age. At the same time, this syndrome represents 
about 75% of the causes of endocrine infertility and 95% of the causes of hirsutism.  
Aim of the study. The purpose of the study was to select the groups of drugs used in the 
treatment of polycystic ovary syndrome and to analyse their presence on the pharmaceutical 
market with argument of the rationality of use.  
Materials and methods. The specialized literature was analysed with the selection of the 
groups and drugs recommended in the pharmacotherapy of polycystic ovary syndrome with 
the argument of the pathophysiological mechanisms responsible for their effectiveness. Based 
on the study of the State Nomenclature of Medicines, were selected the groups of drugs present 
on the pharmaceutical market in the Republic of Moldova.  
Results. In the Republic of Moldova are registered metformin (oral antidiabetic biguanide) and 
combination medication (with glibenclamide, sitagliptin, vildagliptin), saxagliptin (oral 
antidiabetic, dipeptidyl-peptidase-IV inhibitor), letrozole (aromatase inhibitor), ciproterone, 
flutamide , finasteride (antiandrogen), clomiphene (estrogen receptor modulators), oral 
contraceptives (estrogen-progestin), spironolactone (aldosterone antagonist and antiandrogen), 
gonadotropins, myoinositol and simvastatin (hypolipemic statins). The use of oral antidiabetics 
is determined by the diminution of insulin resistance and metabolic effects that accompany the 
metabolic syndrome (obesity, dyslipidemias, hyperinsulinemia, hyperglycemia). 
Antiandrogenic preparations, aromatase inhibitors, spironolactone and oral contraceptives will 
contribute to the combat against hyperanderogenism and hirsutism. Hypolipidemic statins will 
result in decreased cholesterol synthesis and steroidogenesis with excessive testosterone 
synthesis. Gonadotropin drugs will be used for ovulation and pregnancy. Myoinositol and 
polyvitamin and mineral supplements will help correct metabolic disorders.  
Conclusions. The study established the presence of groups of drugs used in the treatment of 
polycystic ovary syndrome in the State Nomenclature of Medicines, which will influence the 
pathogenetic links of the disease.  
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Introduction. Migraine is a recurrent headache disorder affecting ∼15% of the population 
during the most productive periods of their lives, between the ages of 22 and 55 years. Chronic 
migraine is no longer considered a complication of migraine and is recognized in individuals 
